Search the Newsreel

SI-BONE Inc (SIBN) Earnings Forecast: Future EPS & Revenue Growth Estimates

The SI-BONE, Inc. (NASDAQ:SIBN) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

SI-BONE, Inc. reported second-quarter results showing revenues in line with analyst predictions and smaller-than-expected statutory losses. Analysts have moderately uplifted their sentiment, improving loss per share forecasts for 2026, though the consensus price target of US$25.00 remains unchanged. The company is forecast to grow …

BlackRock, Inc. Adds to SI-BONE Inc (SIBN) Stake -- Shares Trade 13% Below GF Value

BlackRock, Inc. has increased its stake in SI-BONE Inc (SIBN), a medical device company, by purchasing 130,194 additional shares. This transaction suggests SI-BONE is "Modestly Undervalued" according to GuruFocus's GF Valuation, trading approximately 13% below its intrinsic value. Despite current profitability concerns, the move …

SI-BONE, Inc. (SIBN) director sells 20,000 shares after option exercise

SI-BONE director Jeffrey W. Dunn exercised stock options for 20,000 shares at $4.68 per share and simultaneously sold all 20,000 shares at a weighted-average price of $18.4607. These transactions were executed on August 3, 2026, under a Rule 10b5-1 trading plan established on May …

SI-BONE, Inc. 2026: Revenue $56.01M, EPS ($0.09) — 10-Q Summary

SI-BONE, Inc. reported strong financial results for the quarter ended 2026, with revenue increasing by 15.2% year-over-year to $56.01M and a significant reduction in net loss and diluted EPS. The company highlighted revenue growth driven by increased procedure volume, a shift towards ASCs and …

SI-BONE (SIBN) Stock Holds Firm As Losses Narrow and Growth Continues

SI-BONE, Inc. Stock 12‑Month Price Target Raised to $25, Implies 36% Upside

Analysts have raised the 12-month price target for SI-BONE, Inc. (SIBN) stock from $24.44 to $25, with an implied potential upside of approximately 36% based on the recent closing price. The consensus rating among 9 covering analysts remains a "Buy," with no "Holds" or …

UBS Lifts Price Target on SI-BONE to $25 From $24, Maintains Buy Rating

UBS has increased its price target for SI-BONE (SIBN) shares to $25 from $24, while maintaining a Buy rating on the stock. This adjustment follows SI-BONE's recent Q2 2026 earnings report, where

Canaccord reiterates SI-BONE stock rating on strong Q2 results

Canaccord Genuity has reiterated a Buy rating and a $27.00 price target for SI-BONE Inc. (NASDAQ:SIBN) following strong Q2 2026 results where the company beat bottom-line expectations and raised revenue guidance. Despite the positive performance and financial flexibility from holding more cash than debt, …

SI-BONE Reports Q2 2026: $56.0M Revenue, Positive Adjusted EBITDA of $2.8M, Raises 2026 Revenue Guidance

SI-BONE (SIBN) reported strong second-quarter 2026 results, with revenue of $56.0 million, a 15.2% year-over-year increase, and positive adjusted EBITDA of $2.8 million. The company also improved its net loss and increased its full-year 2026 revenue guidance to $231 million–$233 million, driven by growth …

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance

SI-BONE, Inc. reported strong financial results for the second quarter of 2026, including a 15.2% increase in worldwide revenue to $56.0 million and a 178% improvement in adjusted EBITDA to $2.8 million. The company also raised its fiscal year 2026 revenue guidance to a …

SIBN Looks 10.6% Undervalued on GF Value™ Despite Unprofitability

SI-BONE Inc. (SIBN) has reaffirmed its fiscal 2026 gross margin guidance at 79% and lowered its operating expense forecast to 12%, demonstrating a focus on cost optimization despite being unprofitable. The company's Price-to-Sales ratio of 3.91 is below its historical median, indicating tempered market …

SIBN Q2 FY2026 earnings call

SI-BONE, Inc. reported strong Q2 FY2026 results with worldwide revenue of $56.0 million, up 15.2% year-over-year, and a significant improvement in adjusted EBITDA. The company saw robust U.S. procedure volume growth and is on track for a phased commercial launch of its third breakthrough …

Earnings call transcript: SI-BONE tops Q2 2026 estimates, shares fall after hours

SI-BONE (SIBN) exceeded Wall Street's expectations for Q2 2026, reporting a smaller adjusted loss and slightly higher revenue due to strong procedure volumes and improved efficiency. Despite the beat, the company's shares fell in after-hours trading as investors focused on the future outlook and …

SI-BONE raises 2026 worldwide revenue outlook to $231 million-$233 million

SI-BONE has increased its 2026 worldwide revenue guidance to $231-$233 million, representing a 15%-16% year-over-year growth from its previous outlook of $230-$233 million. The company maintained its gross margin outlook at approximately 79% and revised operating expense expectations to about 12% at the midpoint. …

Earnings Flash (SIBN) SI-BONE, Inc. Reports Q2 Revenue $56.0M, vs. FactSet Est of $55.3M

SI-BONE, Inc. reported its second-quarter revenue of $56.0 million, surpassing the FactSet estimate of $55.3 million. The medical device company also posted a Q2 loss of $0.09 per share, which was better than the FactSet estimate of a $0.15 loss. These results were published …

SI-BONE Q2 2026 Earnings: Revenue Rises 15.2% as Loss Narrows

SI-BONE reported strong Q2 2026 results with a 15.2% increase in revenue to $56.0 million and a narrowed diluted loss per share to $0.09. The company's U.S. procedure growth was a key driver, supported by an expanding physician base and increased territory productivity. SI-BONE …

SIBN Looks 10.6% Undervalued on GF Value™ Amid Strong Growth Prospects

SI-BONE Inc (SIBN) reported Q2 revenue of $56 million, exceeding analyst expectations

Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates

Si-Bone (SIBN) reported a Q2 loss of $0.09 per share, exceeding the Zacks Consensus Estimate of a $0.15 loss and surpassing last year's $0.14 loss. The medical device maker also topped revenue estimates with $56.01 million, outperforming the $48.63 million from the previous year. …

Responsive Playbooks and the SIBN Inflection

This article analyzes Si-bone Inc. (NASDAQ: SIBN) using AI models, highlighting a strong near-term sentiment but neutral mid and long-term outlook. It identifies resistance being tested and presents three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels for …

SI-BONE (Nasdaq:SIBN) - Stock Analysis

This report provides a comprehensive stock analysis of SI-BONE (SIBN), a medical device company. It covers the company's market overview, valuation, future growth prospects, past performance, financial health, dividend policy, management, and ownership. The analysis highlights that SIBN is currently unprofitable but trading below …

SI-BONE Number of Employees 2026 | Employee Count & Headcount Data

SI-BONE, Inc. (SIBN) had approximately 385 employees worldwide as of March 2026, representing a 7.9% growth since 2023. The company is actively hiring, with 46 active job postings in 2026, a 96.8% increase from the previous year. Most of its workforce is located in …

BlackRock, Inc. (SIBN) discloses 3.56M-share, 8% passive stake in SI-BONE

BlackRock, Inc. has disclosed an 8% passive stake in SI-BONE, Inc. common stock, totaling 3,558,735 shares as of June 30, 2026. This ownership, reported in an Amendment No. 7 to Schedule 13G, indicates BlackRock's sole voting power over 3,490,613 shares and sole dispositive power …

Earnings Preview: Si-Bone to Report Financial Results Post-market on August 03

This article announces that Si-Bone (NASDAQ: SIBN) is scheduled to release its financial results after market close on August 3. The company is expected to report an EPS of -$0.30 and revenue of $37.58 million, according to analyst estimates. These figures will be compared …

SIBN Initiated Coverage by UBS -- Price Target Announced at $24

UBS has initiated coverage on SI-BONE (SIBN) with a "Buy" rating and a price target of $24.00, suggesting significant upside potential. GuruFocus assesses SIBN as 13.1% undervalued with a GF Value™ of $20.59, despite the company currently being unprofitable. The stock boasts a strong …

SI-BONE Inc (SIBN) Financial Health: Profitability & Balance Sheet Analysis

SI-BONE Inc (SIBN) currently holds a financial score of 7.73, ranking 61st out of 199 in the Healthcare Equipment & Supplies industry. The company exhibits robust financial status and high operating efficiency, with its latest quarterly revenue climbing 11.20% year-over-year to $52.59 million, and …

SI-BONE Inc (SIBN) Institutional Confidence

SI-BONE Inc (SIBN) has an institutional shareholding score of 10.00, placing it first within the Healthcare Equipment & Supplies industry. Institutional shareholding stands at 103.63%, a slight decrease from the previous quarter. Steven Cohen is the largest institutional shareholder, holding 733.75K shares, representing 1.90% …

SI-BONE Inc (SIBN) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for SI-BONE Inc (SIBN), covering operating, investing, and financing activities. It presents financial figures alongside year-over-year percentage changes for various cash flow components. The report also includes an FAQ section defining different types …

SI-BONE Inc (SIBN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for SI-BONE Inc (SIBN), highlighting regional contributions. As of April 6, the United States accounts for 95.10% of the company's revenue, totaling $191.08 million, while international operations contribute 4.90% with $9.85 million. The report notes that relevant data …

SIBN|SI-BONE Inc|Price:16.470|Chg%:-0.240

This article provides an overview of SI-BONE Inc. (SIBN), a medical device company specializing in surgical implant systems for sacropelvic disorders. It details the company's products like iFuse and iFuse-3D, lists key executives and their shareholdings, and includes information on institutional ownership. The company's …

Understanding the Setup: (SIBN) and Scalable Risk

This article analyzes Si-bone Inc. (NASDAQ: SIBN), highlighting weak near-term sentiment and a mid-channel oscillation pattern. It identifies an exceptional 57.2:1 risk-reward short setup with a 15.9% downside target versus 0.3% risk. The piece also outlines specific institutional trading strategies, including position trading, momentum …

SI-BONE to report second quarter 2026 results on August 3

SI-BONE, Inc. will release its financial results for the second quarter of 2026 after the market closes on Monday, August 3, 2026. Management will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results and provide …

SI-BONE to report Q2 2026 results, host conference call

SI-BONE Inc. is scheduled to report its second-quarter 2026 financial results on August 3, 2026. Following the release, the company will host a management conference call on the same day at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results. Interested parties can …